Quarterly report pursuant to Section 13 or 15(d)

7. SEGMENTS

v3.5.0.2
7. SEGMENTS
9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
7. SEGMENTS

The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. The Company also operates ADMA BioCenters, consisting of two FDA-licensed source plasma collection facilities located in Georgia .  The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer.

 

The plasma collection centers segment includes the Company’s operations in Georgia.  The research and development segment includes the Company’s plasma development operations in New Jersey.

  

Summarized financial information concerning reportable segments is shown in the following tables:

 

    Plasma                    
Three Months Ended   Collection     Research and              
September 30, 2016   Centers     Development     Corporate     Consolidated  
                         
Revenues   $ 2,902,155     $ -     $ 35,708     $ 2,937,863  
Cost of product revenue     1,735,771       -       -       1,735,771  
Gross profit     1,166,384       -       35,708       1,202,092  
Loss from operations     (316,202 )     (1,677,263 )     (1,743,407 )     (3,736,872 )
Other expense, net     -       -       (594,367 )     (594,367 )
Net loss     (316,202 )     (1,677,263 )     (2,337,774 )     (4,331,239 )
Total assets     2,707,636       -       24,787,750       27,495,386  
Depreciation and                                
amortization expense     103,493       -       13,815       117,308  

 

    Plasma                    
Three Months Ended   Collection     Research and              
September 30, 2015   Centers     Development     Corporate     Consolidated  
                         
Revenues   $ 1,821,229     $ -     $ 31,184     $ 1,852,413  
Cost of product revenue     1,112,782       -       -       1,112,782  
Gross profit     708,447       -       31,184       739,631  
Loss from operations     (505,711 )     (2,111,505 )     (2,046,982 )     (4,664,198 )
Other expense, net     -       -       (438,226 )     (438,226 )
Net loss     (505,711 )     (2,111,505 )     (2,485,208 )     (5,102,424 )
Total assets     3,074,076       -       24,749,954       27,824,030  
Depreciation and                                
amortization expense     105,192       -       12,738       117,930  

  

    Plasma                    
Nine Months Ended   Collection     Research and              
September 30, 2016   Centers     Development     Corporate     Consolidated  
                         
Revenues   $ 7,226,368     $ -     $ 107,125     $ 7,333,493  
Cost of product revenue     4,346,433       -       -       4,346,433  
Gross profit     2,879,935       -       107,125       2,987,060  
Loss from operations     (1,177,371 )     (7,104,864 )     (5,104,023 )     (13,386,258 )
Other expense, net     -       -       (1,569,785 )     (1,569,785 )
Net loss     (1,177,371 )     (7,104,864 )     (6,673,808 )     (14,956,043 )
Total assets     2,707,636       -       24,787,750       27,495,386  
Depreciation and                                
amortization expense     311,012       -       40,690       351,702  

 

    Plasma                    
Nine Months Ended   Collection     Research and              
September 30, 2015   Centers     Development     Corporate     Consolidated  
                         
Revenues   $ 4,596,490     $ -     $ 68,962     $ 4,665,452  
Cost of product revenue     2,808,726       -       -       2,808,726  
Gross profit     1,787,764       -       68,962       1,856,726  
Loss from operations     (1,571,366 )     (5,019,138 )     (4,792,636 )     (11,383,140 )
Other expense, net     -       -       (2,004,137 )     (2,004,137 )
Net loss     (1,571,366 )     (5,019,138 )     (6,796,773 )     (13,387,277 )
Total assets     3,074,076       -       24,749,954       27,824,030  
Depreciation and                                
amortization expense     315,209       -       37,420       352,629  

 

The “Corporate” column above includes general and administrative overhead expenses.  Total assets included in the “Corporate” column above includes assets related to corporate and support functions.